{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:54Z","timestamp":1790963034507,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41391-025-00959-8","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:55:07Z","timestamp":1742954107000},"page":"198-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK"],"prefix":"10.1038","volume":"29","author":[{"given":"Ugo","family":"De Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-6419","authenticated-orcid":false,"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4261-3484","authenticated-orcid":false,"given":"Antti","family":"Rannikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Ramirez-Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnauld","family":"Villers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"959_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75:967\u201387.","journal-title":"Eur Urol"},{"key":"959_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102630","volume":"122","author":"JA Efstathiou","year":"2024","unstructured":"Efstathiou JA, Morgans AK, Bland CS, Shore ND. Novel Hormone Therapy and Coordination of Care in High-risk Biochemically Recurrent Prostate Cancer. Cancer Treat Rev. 2024;122:102630.","journal-title":"Cancer Treat Rev"},{"key":"959_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024;211:509\u201317.","journal-title":"J Urol"},{"key":"959_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211:518\u201325.","journal-title":"J Urol"},{"key":"959_CR5","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Briers E, Patient Advocate (European Prostate Cancer Coalition\/Europa UOMO), Eberli D, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. 2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2024_2024-04-09-132035_ypmy.pdf."},{"key":"959_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med"},{"key":"959_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2300251","DOI":"10.1056\/EVIDoa2300251","volume":"2","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJM Evid. 2023;2:EVIDoa2300251.","journal-title":"NEJM Evid"},{"key":"959_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","volume":"75","author":"D Tilki","year":"2019","unstructured":"Tilki D, Preisser F, Graefen M, Huland H, Pompe RS. External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. Eur Urol. 2019;75:896\u2013900.","journal-title":"Eur Urol"},{"key":"959_CR9","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","volume":"34","author":"BJ Stish","year":"2016","unstructured":"Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, et al. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016;34:3864\u201371.","journal-title":"J Clin Oncol"},{"key":"959_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/JCO.23.00949","volume":"42","author":"J Gong","year":"2024","unstructured":"Gong J, Kim DM, De Hoedt AM, Bhowmick N, Figlin R, Kim HL, et al. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? J Clin Oncol. 2024;42:228\u201336.","journal-title":"J Clin Oncol"},{"key":"959_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41585-023-00828-w","volume":"21","author":"J Gong","year":"2024","unstructured":"Gong J, Kim DM, Freeman MR, Kim H, Ellis L, Smith B, et al. Genetic and biological drivers of prostate cancer disparities in Black men. Nat Rev Urol. 2024;21:274\u201389.","journal-title":"Nat Rev Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00959-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:46Z","timestamp":1771272166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00959-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["959"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00959-8","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UDG reports consulting for Amgen, Astellas Pharma Inc., AstraZeneca, Bayer, Bristol Myers Squibb, Esai, Ipsen, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer Inc., and Roche; receiving travel expenses from AstraZeneca, Ipsen, Pfizer Inc., Roche, and Sanofi; and having other financial or non-financial interests in AstraZeneca, Roche, and Sanofi. SJF reports consulting for Astellas Pharma Inc., AstraZeneca, Bayer, Eli Lilly, Exact Sciences, Johnson & Johnson Innovative Medicine (formerly Janssen), Merck, Novartis, Pfizer Inc., Sanofi, and Sumitomo Pharma America, Inc. (formerly Myovant Sciences). AR reports being an advisory board member for Bayer, Johnson & Johnson Innovative Medicine (formerly Janssen), and Orion Pharma; holding a leadership role in the Orion Research Foundation (board chair); and being a member of the board for the Ida Montin Research Foundation. MR-B reports consulting and receiving honoraria from Astellas Pharma Inc., Bayer, and Johnson & Johnson Innovative Medicine (formerly Janssen); receiving payment for expert testimony from Johnson & Johnson Innovative Medicine (formerly Janssen); and receiving travel, accommodation, and expenses from Astellas Pharma Inc. and Johnson & Johnson Innovative Medicine (formerly Janssen). AV reports consulting for Astellas Pharma Inc., AstraZeneca, Ipsen, and Johnson & Johnson Innovative Medicine (formerly Janssen). JT reports being a former employee of and shareholder in Pfizer Inc. YT reports being an employee of and shareholder in Pfizer Inc. GPH reports being an employee of Astellas Pharma Inc.; and stock ownership in Sumitomo Pharma America, Inc. (formerly Myovant Sciences). MR reports being an employee of and shareholder in Astellas Pharma Inc. NDS reports consulting for or receiving research funding from Accord, Alessa Therapeutics, Amgen, Antev, Arquer, Asieris, Astellas Pharma Inc., AstraZeneca, Aura, Bayer, Bristol Myers Squibb, Boston Scientific, CG Oncology (formerly Cold Genesys), Clarity, Clovis Oncology, Dendreon, Eli Lilly, Exact Imaging, Ferring, Fize Medical, Foundation Medicine, GenesisCare US, Guardant Health, Immunitybio, Incyte, InVitae, Johnson & Johnson Innovative Medicine (formerly Janssen), Lantheus, MDxHealth, Merck, Minomic, Myriad, NGM, Nonagen, Novartis, Pfizer Inc., Photocure, PlatformQ, Point Biopharma, Promaxo, Propella, Protara, Sanofi, Specialty Networks, Steba, Sumitomo, Telix, Theralase, Tolmar, Urogen, and Zenflow.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}